Who
Arjun Agarwal
Senior Vice President, Finance
Company insider
Files Form 4 as: Senior Vice President, Finance, Oruka Therapeutics.
In numbers
- Trades disclosed
- 105
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $9.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 22 Jan 2025
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $107K8,541 at $12.50 | filing |
| 12 Oct 2026filed 13 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K1,458 at $34.39 | filing |
| 12 Oct 2026filed 13 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $459K5,741 at $80.03 | filing |
| 12 Oct 2026filed 13 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $170K2,100 at $80.76 | filing |
| 12 Oct 2026filed 13 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $160K1,958 at $81.86 | filing |
| 12 Oct 2026filed 13 Oct 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $17K200 at $82.84 | filing |
| 12 Oct 2026filed 13 Oct 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,541 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,458 at $0.00 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $51K533 at $95.75 | filing |
| 21 Sep 2026filed 21 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $51K533 at $95.75 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $54K560 at $95.71 | filing |
| 15 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $54K560 at $95.71 | filing |
| 11 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $100K8,000 at $12.50 | filing |
| 11 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K1,459 at $34.39 | filing |
| 11 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $273K3,000 at $91.11 | filing |
| 11 Sep 2026filed 15 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,000 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | ORKA Oruka Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,459 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $374K4,051 at $92.41 | filing |
| 11 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $206K2,208 at $93.26 | filing |
| 11 Sep 2026filed 15 Sep 2026 | ORKA Oruka TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K200 at $94.02 | filing |
News
No headline names them, or the companies they trade most, lately.